NL301035I1 - upadacitinib of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

upadacitinib of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301035I1
Authority: NL; Netherlands
Prior art keywords: upadacitinib; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2009-12-01

Application number

NL301035C

Other languages

English (en)

Other versions

NL301035I2 (nl

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-01

Filing date

2020-03-17

Publication date

2020-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301035(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-03-17 Application filed by Abbvie Inc filed Critical Abbvie Inc

2020-03-25 Publication of NL301035I1 publication Critical patent/NL301035I1/nl

2020-04-15 Publication of NL301035I2 publication Critical patent/NL301035I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Virology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)

NL301035C 2009-12-01 2020-03-17 upadacitinib of een farmaceutisch aanvaardbaar zout daarvan NL301035I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26556309P	2009-12-01	2009-12-01
US36411610P	2010-07-14	2010-07-14
PCT/US2010/058572 WO2011068881A1 (en)	2009-12-01	2010-12-01	Novel tricyclic compounds

Publications (2)

Publication Number	Publication Date
NL301035I1 true NL301035I1 (nl)	2020-03-25
NL301035I2 NL301035I2 (nl)	2020-04-15

Family

ID=44070404

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301035C NL301035I2 (nl)	2009-12-01	2020-03-17	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan

Country Status (41)

Country	Link
US (5)	US8426411B2 (nl)
EP (3)	EP3266786A1 (nl)
JP (3)	JP5607174B2 (nl)
KR (3)	KR20170118230A (nl)
CN (4)	CN108774237A (nl)
AR (1)	AR079234A1 (nl)
AU (4)	AU2010326108C1 (nl)
BR (1)	BR112012013349B1 (nl)
CA (2)	CA2991896A1 (nl)
CL (1)	CL2012001397A1 (nl)
CO (1)	CO6561771A2 (nl)
CR (2)	CR20170159A (nl)
CY (2)	CY1119175T1 (nl)
DK (1)	DK2506716T3 (nl)
DO (2)	DOP2012000151A (nl)
EC (1)	ECSP12011979A (nl)
ES (1)	ES2637588T3 (nl)
HK (1)	HK1256947A1 (nl)
HR (1)	HRP20171175T1 (nl)
HU (2)	HUE033099T2 (nl)
IL (4)	IL220054A (nl)
LT (2)	LT2506716T (nl)
LU (1)	LUC00149I2 (nl)
ME (1)	ME02800B (nl)
MX (1)	MX346959B (nl)
MY (1)	MY167076A (nl)
NL (1)	NL301035I2 (nl)
NO (1)	NO2020006I1 (nl)
NZ (1)	NZ600161A (nl)
PE (1)	PE20121336A1 (nl)
PH (2)	PH12012501076B1 (nl)
PL (1)	PL2506716T3 (nl)
PT (1)	PT2506716T (nl)
RS (1)	RS56317B1 (nl)
RU (2)	RU2570416C9 (nl)
SG (2)	SG10201407976UA (nl)
SI (1)	SI2506716T1 (nl)
TW (3)	TWI500620B (nl)
UY (1)	UY33071A (nl)
WO (1)	WO2011068881A1 (nl)
ZA (1)	ZA201203999B (nl)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS54560B1 (en)	2008-06-10	2016-06-30	Abbvie Inc.	TRICYCLIC UNITS
CN102395589A (zh) *	2009-04-14	2012-03-28	安斯泰来制药株式会社	稠合吡咯并吡啶衍生物
ME02800B (me) *	2009-12-01	2018-01-20	Abbvie Inc	Nova triciklična jedinjenja
PH12012501000A1 (en) *	2009-12-01	2013-02-11	Abbvie Inc	Novel tricyclic compounds
US8461328B2 (en)	2010-01-12	2013-06-11	Genentech, Inc.	Tricyclic heterocyclic compounds, compositions and methods of use thereof
JP6277121B2 (ja) *	2011-03-22	2018-02-07	アドヴィナス・セラピューティックス・リミテッド	置換された縮合三環式化合物、その組成物および医学的応用
CA2831680C (en)	2011-04-21	2020-04-21	Origenis Gmbh	Heterocyclic compounds as kinase inhibitors
WO2013007765A1 (en) *	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Fused tricyclic compounds for use as inhibitors of janus kinases
RU2632870C2 (ru) *	2011-08-12	2017-10-11	Ниссан Кемикал Индастриз, Лтд.	Трициклические гетероциклические соединения и ингибиторы jak
US20130072470A1 (en) *	2011-09-21	2013-03-21	Abbvie Inc.	Novel tricyclic compounds
CN102516146B (zh) *	2011-11-24	2013-10-02	爱斯特（成都）生物制药有限公司	5位为氮的四元氮杂螺环衍生物及其制备方法和用途
US9593115B2 (en)	2012-09-21	2017-03-14	Advinus Therapeutics Ltd.	Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
WO2014060113A1 (en)	2012-10-19	2014-04-24	Origenis Gmbh	Novel kinase inhibitors
JP6248948B2 (ja) *	2013-02-08	2017-12-20	日産化学工業株式会社	３環性ピロロピリジン化合物及びｊａｋ阻害剤
DK3290421T3 (en)	2013-02-22	2019-03-18	Pfizer	COMBINATION OF PYRROLO [2, 3-D] PYRIMIDINE DERIVATIVES AND ONE OR MORE ADDITIONAL SUBSTANCES AS JANUS-RELATED KINASES (JAK) INHIBITORS
WO2014134281A1 (en)	2013-02-28	2014-09-04	Full Spectrum Laboratories Limited	Biosynthesis of cannabinoids
AU2014306759B2 (en)	2013-08-12	2018-04-26	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
AU2014339897A1 (en) *	2013-10-24	2016-04-21	Abbvie Inc.	JAK1 selective inhibitor and uses thereof
US10172797B2 (en)	2013-12-17	2019-01-08	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
EP3129373B1 (en) *	2014-04-11	2021-09-01	Taipei Medical University	Histone deacetylase inhibitors
CA2944433A1 (en)	2014-05-14	2015-11-19	Nissan Chemical Industries, Ltd.	Tricyclic compound and jak inhibitor
ES2809458T3 (es)	2014-07-17	2021-03-04	Pharmaceutical Manufacturing Res Services Inc	Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
ES2750655T3 (es)	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
WO2016030828A1 (en)	2014-08-25	2016-03-03	Full Spectrum Laboratories Limited	Apparatus and methods for the simultaneous production of cannabinoid compounds
WO2016064873A1 (en)	2014-10-20	2016-04-28	Pharmaceutical Manufacturing Research Services, Inc.	Extended release abuse deterrent liquid fill dosage form
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR122022024925B1 (pt)	2015-10-16	2023-11-28	Abbvie Inc	Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil) pirroli-dina-1-carboxamida
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10196396B2 (en)	2016-01-14	2019-02-05	Handok Inc.	Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
US20190086392A1 (en)	2016-03-21	2019-03-21	Inserm (Institut National De La Sante Et De La Recherch Medicale)	Methods for diagnosis and treatment of solar lentigo
MX2019007073A (es)	2016-12-16	2019-10-15	Janssen Pharmaceutica Nv	Inhibidores de moléculas pequeñas de la familia de quinasas jak.
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
US11564922B2 (en)	2017-03-09	2023-01-31	Abbvie Inc.	Methods of treating crohn's disease and ulcerative colitis
BR112019018576A2 (pt)	2017-03-09	2020-04-14	Abbvie Inc	métodos de tratamento de doença de crohn e colite ulcerativa
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US10364245B2 (en)	2017-06-07	2019-07-30	Chiesi Farmaceutici S.P.A.	Kinase inhibitors
CN109535164B (zh) *	2017-09-21	2022-01-18	上海华汇拓医药科技有限公司	Jak激酶抑制剂及其制备方法和在医药领域的应用
JP6557436B1 (ja)	2018-03-12	2019-08-07	アッヴィ・インコーポレイテッド	チロシンキナーゼ２媒介性シグナル伝達の阻害剤
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
CN110872250B (zh) *	2018-08-31	2023-01-10	苏州鹏旭医药科技有限公司	两种化合物及其制备方法和在合成乌西替尼中的用途
WO2020043033A2 (zh) *	2018-08-31	2020-03-05	苏州鹏旭医药科技有限公司	一种乌帕替尼及其中间体的合成方法
TWI842766B (zh) *	2018-11-01	2024-05-21	大陸商凌科藥業有限公司	三環janus 激酶1 抑制劑及其組合物和方法
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
CN111217819B (zh) *	2018-11-27	2021-05-14	杭州科巢生物科技有限公司	乌帕替尼的合成方法
EP3891151A1 (en)	2018-12-05	2021-10-13	LEK Pharmaceuticals d.d.	Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
WO2020115213A1 (en)	2018-12-07	2020-06-11	Lek Pharmaceuticals D.D.	Solvate of a selective jak1 inhibitor
CN109761885B (zh) *	2019-02-21	2020-06-26	北京悦康科创医药科技股份有限公司	一种阿加曲班异构体杂质的拆分方法
CN112888692A (zh) *	2019-03-01	2021-06-01	苏州科睿思制药有限公司	一种Upadacitinib的晶型及其制备方法和用途
PH12021552130A1 (en)	2019-03-05	2022-08-31	Incyte Corp	Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EP3939979A4 (en)	2019-03-14	2022-04-06	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	KINASE JAK INHIBITOR, METHOD FOR PREPARING IT AND ITS APPLICATIONS IN THE FIELD OF MEDICINE
WO2020202183A1 (en)	2019-03-29	2020-10-08	Mylan Laboratories Limited	The process for the preparation of upadacitinib and its intermediates
CN111909160B (zh) *	2019-05-09	2024-05-28	苏州鹏旭医药科技有限公司	一种乌帕替尼盐类化合物及其制备方法
JP7371221B2 (ja) *	2019-07-26	2023-10-30	珠海宇繁生物科技有限責任公司	Ｉｒａｋ４キナーゼ阻害剤及びその調製方法
CN110938048B (zh) *	2019-12-02	2023-03-28	四川大学	路易酸催化的插入反应高效合成二氢呋喃衍生物
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
WO2021123288A1 (en)	2019-12-19	2021-06-24	Crystal Pharma, S.A.U.	Process and intermediates for the preparation of upadacitinib
CN111007184B (zh) *	2019-12-30	2023-05-16	天津天士力圣特制药有限公司	一种4-甲基哌嗪-1-甲酰氯盐酸盐含量的检测方法
WO2021176473A1 (en)	2020-03-05	2021-09-10	Mylan Laboratories Limited	A process for the preparation of upadacitinib and its intermediates
US11718622B2 (en)	2020-03-16	2023-08-08	Exelixis Inc.	Heterocyclic adenosine receptor antagonists
EP4138561A1 (en) *	2020-04-24	2023-03-01	Kansas Soybean Commission	One-step synthesis of soybean polyols
CN114206877B (zh) *	2020-06-05	2024-04-19	苏州科睿思制药有限公司	一种乌帕替尼的晶型及其制备方法和用途
EP4180435A1 (en)	2020-07-08	2023-05-17	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of upadacitinib, preparation method therefor, and use thereof
WO2022044037A1 (en)	2020-08-24	2022-03-03	Mylan Laboratories Limited	An improved process for the preparation of upadacitinib intermediate
CN117015543A (zh) *	2020-09-14	2023-11-07	高德美控股有限公司	新型jak抑制剂化合物、其合成方法及其用途
CN112578034B (zh) *	2020-11-04	2022-02-11	广东众生睿创生物科技有限公司	一种手性胺小分子及其盐的质量控制方法
CN114790208B (zh) *	2021-01-26	2024-06-07	珠海宇繁生物科技有限责任公司	一种irak4激酶抑制剂及其制备方法
AU2022255047A1 (en) *	2021-04-07	2023-10-19	Abbvie Inc.	Cocrystals of upadacitinib
CN113200967B (zh) *	2021-05-07	2022-05-24	中国人民解放军陆军军医大学	吲哚苯醌类化合物、其制备方法及其应用
CN113603693B (zh) *	2021-07-13	2022-08-26	陕西丽彩药业有限公司	一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法
CN114380837B (zh) *	2021-12-27	2023-06-30	上海邈金医药科技有限公司	一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
EP4215196A1 (en)	2022-01-24	2023-07-26	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
CN116836171B (zh) *	2023-06-30	2024-06-04	凌科药业(杭州)有限公司	一种磺酰胺类化合物及其应用
CN117285537B (zh) *	2023-11-27	2024-02-06	中节能万润股份有限公司	一种乌帕替尼的制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB716327A (en)	1951-09-05	1954-10-06	Ici Ltd	New heterocyclic compounds
US3663559A (en)	1969-12-03	1972-05-16	Union Carbide Corp	Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4053474A (en) *	1976-04-21	1977-10-11	E. R. Squibb & Sons, Inc.	Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US5605690A (en)	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5270316A (en)	1989-10-20	1993-12-14	Kyowa Hakko Kogyo Co., Ltd.	Condensed purine derivatives
JP2580091B2 (ja)	1990-01-11	1997-02-12	アイシス・ファーマシューティカルス・インコーポレーテッド	Ｒｎａ活性および遺伝子発現を検出および変調するための組成物および方法
US6262241B1 (en)	1990-08-13	2001-07-17	Isis Pharmaceuticals, Inc.	Compound for detecting and modulating RNA activity and gene expression
DK0559751T3 (da)	1990-11-26	1997-10-06	Robert R Recker	Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH)
EP1857554A1 (en)	1991-03-18	2007-11-21	New York University	Monoclonal and chimeric antibodies specific for human tumor necrosis factor
CA2110942A1 (en)	1991-06-14	1992-12-23	Pharmacia & Upjohn Company Llc	Imidazo¬1,5-a\|quinoxalines
US5212310A (en)	1991-12-19	1993-05-18	Neurogen Corporation	Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en)	1992-04-30	1993-11-30	Neurogen Corporation	Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en)	1992-08-27	1994-04-26	Neurogen Corporation	Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
HUT72640A (en)	1993-02-26	1996-05-28	Schering Corp	2-benzyl-polycyclic guanine derivatives, pharmaceutical compositions containing them and process for preparing them
US5736540A (en)	1993-07-29	1998-04-07	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en)	1993-07-29	1998-03-31	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en)	1994-09-20	1996-08-20	Talley; John J.	Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru)	1994-12-23	2000-10-27	Варнер-Ламберт Компани	Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5753648A (en)	1995-01-17	1998-05-19	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
US5521173A (en)	1995-01-17	1996-05-28	American Home Products Corporation	Tricyclic benzazepine vasopressin antagonists
US5763137A (en)	1995-08-04	1998-06-09	Agfa-Gevaert, N.V.	Method for making a lithographic printing plate
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
EP1066286B1 (en) *	1998-03-04	2009-04-29	Bristol-Myers Squibb Company	Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US6448253B1 (en) *	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
CO5271670A1 (es)	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP4100865B2 (ja) *	1999-12-13	2008-06-11	エーザイ・アール・アンド・ディー・マネジメント株式会社	三環式縮合異項環化合物、その製造法およびその医薬
MXPA03001186A (es)	2000-08-07	2004-04-20	Neurogen Corp	Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
GB0115393D0 (en)	2001-06-23	2001-08-15	Aventis Pharma Ltd	Chemical compounds
GB0124299D0 (en) *	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
JP2005529850A (ja)	2002-02-19	2005-10-06	ファルマシア・イタリア・エス・ピー・エー	三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
WO2004018455A1 (en) *	2002-08-23	2004-03-04	Chiron Corporation	Pyrrole based inhibitors of glycogen synthase kinase 3
DE602004021558D1 (de) *	2003-01-17	2009-07-30	Warner Lambert Co	2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US7176214B2 (en)	2003-05-21	2007-02-13	Bristol-Myers Squibb Company	Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200524864A (en) *	2003-11-10	2005-08-01	Wyeth Corp	Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
WO2005110410A2 (en)	2004-05-14	2005-11-24	Abbott Laboratories	Kinase inhibitors as therapeutic agents
PE20060526A1 (es) *	2004-06-15	2006-07-13	Schering Corp	Compuestos triciclicos como antagonistas de mglur1
DE502005008916D1 (de)	2004-07-23	2010-03-11	Medicines Co Leipzig Gmbh	Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
KR20070089201A (ko)	2004-11-22	2007-08-30	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피롤로피라진 및피라졸로피라진
US7947694B2 (en) *	2005-01-14	2011-05-24	Janssen Pharmaceutica Nv	Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors
AU2006205851A1 (en) *	2005-01-14	2006-07-20	Janssen Pharmaceutica N.V.	5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US20060183758A1 (en)	2005-02-17	2006-08-17	Cb Research And Development, Inc.	Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
CA2603063A1 (en) *	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
US7737279B2 (en) *	2005-05-10	2010-06-15	Bristol-Myers Squibb Company	1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en)	2005-05-12	2009-09-22	Cytopia Research Pty Ltd	Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CN101223168A (zh) *	2005-07-14	2008-07-16	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
CA2615291A1 (en)	2005-07-14	2007-01-18	Astellas Pharma Inc.	Heterocyclic janus kinase 3 inhibitors
EP1912636B1 (en)	2005-07-21	2014-06-25	Ardea Biosciences, Inc.	N-(arylamino)-sulfonamide inhibitors of mek
KR20080035698A (ko) *	2005-08-16	2008-04-23	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물 및 조성물
BRPI0616338A2 (pt)	2005-09-23	2011-06-14	Coley Pharm Group Inc	mÉtodo para 1h-imidazo[4,5-c] piridinas e anÁlogos da mesma
CN101321760A (zh) *	2005-10-06	2008-12-10	先灵公司	作为蛋白激酶抑制剂的吡唑并嘧啶
ES2390135T3 (es)	2005-11-22	2012-11-06	Merck Sharp & Dohme Corp.	Compuestos tricíclicos útiles como inhibidores de quinasas
CN101389630A (zh)	2005-12-29	2009-03-18	艾博特公司	蛋白激酶抑制剂
US8546368B2 (en) *	2006-02-15	2013-10-01	Abbvie Inc.	Pyrazoloquinolones are potent PARP inhibitors
WO2007143434A2 (en)	2006-05-31	2007-12-13	Takeda San Diego, Inc.	Indazole and isoindole derivatives as glucokinase activating agents
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
US8063225B2 (en)	2006-08-14	2011-11-22	Chembridge Corporation	Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CN101553224A (zh)	2006-10-06	2009-10-07	艾博特公司	新型咪唑并噻唑和咪唑并唑
EP2123651A4 (en)	2007-01-12	2011-05-04	Astellas Pharma Inc	CONDENSED PYRIDINE COMPOUND
JP2010516812A (ja) *	2007-01-30	2010-05-20	バイオジェン・アイデック・エムエイ・インコーポレイテッド	有糸分裂キナーゼの調節剤
WO2008112695A2 (en) *	2007-03-12	2008-09-18	Irm Llc	Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7691869B2 (en) *	2007-03-30	2010-04-06	King Pharmaceuticals Research And Development, Inc.	Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
EP2145012A2 (en)	2007-04-04	2010-01-20	F. Hoffmann-Roche AG	Microbial reduction of an acetoxyketone
US8188083B2 (en) *	2007-06-28	2012-05-29	Abbott Laboratories	Triazolopyridazines
CA2924436A1 (en)	2007-07-30	2009-02-05	Ardea Biosciences, Inc.	Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
AR070558A1 (es) *	2008-02-06	2010-04-21	Novartis Ag	Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas.
WO2009106445A1 (en)	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
JP5368485B2 (ja)	2008-02-25	2013-12-18	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼインヒビター
CN101952294B (zh)	2008-02-25	2014-11-26	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
WO2009108827A1 (en)	2008-02-29	2009-09-03	Wyeth	Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
RS54560B1 (en) *	2008-06-10	2016-06-30	Abbvie Inc.	TRICYCLIC UNITS
US20110201599A1 (en) *	2008-07-03	2011-08-18	Exelixis, Inc.	CDK Modulators
CN102395589A (zh) *	2009-04-14	2012-03-28	安斯泰来制药株式会社	稠合吡咯并吡啶衍生物
US8361962B2 (en) *	2009-07-27	2013-01-29	Roche Palo Alto Llc	Tricyclic inhibitors of JAK
PH12012501000A1 (en) *	2009-12-01	2013-02-11	Abbvie Inc	Novel tricyclic compounds
ME02800B (me)	2009-12-01	2018-01-20	Abbvie Inc	Nova triciklična jedinjenja
US8637529B2 (en)	2010-06-11	2014-01-28	AbbYie Inc.	Pyrazolo[3,4-d]pyrimidine compounds
WO2012149280A2 (en)	2011-04-29	2012-11-01	Abbott Laboratories	Novel tricyclic compounds
US20130072470A1 (en)	2011-09-21	2013-03-21	Abbvie Inc.	Novel tricyclic compounds
AU2014339897A1 (en)	2013-10-24	2016-04-21	Abbvie Inc.	JAK1 selective inhibitor and uses thereof
BR122022024925B1 (pt)	2015-10-16	2023-11-28	Abbvie Inc	Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil) pirroli-dina-1-carboxamida

2010
- 2010-12-01 ME MEP-2017-167A patent/ME02800B/me unknown
- 2010-12-01 HU HUE10835061A patent/HUE033099T2/en unknown
- 2010-12-01 PH PH1/2012/501076A patent/PH12012501076B1/en unknown
- 2010-12-01 MY MYPI2012700314A patent/MY167076A/en unknown
- 2010-12-01 BR BR112012013349A patent/BR112012013349B1/pt active IP Right Grant
- 2010-12-01 NZ NZ600161A patent/NZ600161A/en unknown
- 2010-12-01 PE PE2012000745A patent/PE20121336A1/es active IP Right Grant
- 2010-12-01 AU AU2010326108A patent/AU2010326108C1/en active Active
- 2010-12-01 SG SG10201407976UA patent/SG10201407976UA/en unknown
- 2010-12-01 CA CA2991896A patent/CA2991896A1/en not_active Abandoned
- 2010-12-01 LT LTEP10835061.2T patent/LT2506716T/lt unknown
- 2010-12-01 DK DK10835061.2T patent/DK2506716T3/en active
- 2010-12-01 CR CR20170159A patent/CR20170159A/es unknown
- 2010-12-01 MX MX2012006311A patent/MX346959B/es active IP Right Grant
- 2010-12-01 JP JP2012542161A patent/JP5607174B2/ja active Active
- 2010-12-01 CN CN201810448360.6A patent/CN108774237A/zh active Pending
- 2010-12-01 KR KR1020177027803A patent/KR20170118230A/ko active Application Filing
- 2010-12-01 EP EP17171010.6A patent/EP3266786A1/en not_active Withdrawn
- 2010-12-01 PL PL10835061T patent/PL2506716T3/pl unknown
- 2010-12-01 TW TW099141754A patent/TWI500620B/zh active
- 2010-12-01 RU RU2012127306A patent/RU2570416C9/ru not_active IP Right Cessation
- 2010-12-01 WO PCT/US2010/058572 patent/WO2011068881A1/en active Application Filing
- 2010-12-01 EP EP10835061.2A patent/EP2506716B1/en active Active
- 2010-12-01 UY UY0001033071A patent/UY33071A/es active IP Right Grant
- 2010-12-01 TW TW106122295A patent/TW201802091A/zh unknown
- 2010-12-01 SG SG2012040465A patent/SG181472A1/en unknown
- 2010-12-01 PT PT108350612T patent/PT2506716T/pt unknown
- 2010-12-01 RS RS20170760A patent/RS56317B1/sr unknown
- 2010-12-01 EP EP21173353.0A patent/EP3950692A1/en active Pending
- 2010-12-01 ES ES10835061.2T patent/ES2637588T3/es active Active
- 2010-12-01 TW TW104119191A patent/TWI600656B/zh not_active IP Right Cessation
- 2010-12-01 US US12/958,115 patent/US8426411B2/en not_active Ceased
- 2010-12-01 AR ARP100104438A patent/AR079234A1/es active IP Right Grant
- 2010-12-01 CN CN201080062920.6A patent/CN102711476B/zh active Active
- 2010-12-01 KR KR1020127017105A patent/KR101785257B1/ko active Protection Beyond IP Right Term
- 2010-12-01 CN CN201810902092.0A patent/CN109053742B/zh active Active
- 2010-12-01 CN CN201410571754.2A patent/CN104370909B/zh active Active
- 2010-12-01 KR KR1020187025442A patent/KR20180101626A/ko active Application Filing
- 2010-12-01 RU RU2015144809A patent/RU2711869C3/ru active Protection Beyond IP Right Term
- 2010-12-01 CA CA2781891A patent/CA2781891C/en active Active
- 2010-12-01 SI SI201031517T patent/SI2506716T1/sl unknown
2012
- 2012-05-29 IL IL220054A patent/IL220054A/en active Protection Beyond IP Right Term
- 2012-05-30 DO DO2012000151A patent/DOP2012000151A/es unknown
- 2012-05-30 CL CL2012001397A patent/CL2012001397A1/es unknown
- 2012-05-31 ZA ZA2012/03999A patent/ZA201203999B/en unknown
- 2012-06-18 EC ECSP12011979 patent/ECSP12011979A/es unknown
- 2012-06-22 CO CO12105210A patent/CO6561771A2/es active IP Right Grant
- 2012-06-25 CR CR20120348A patent/CR20120348A/es unknown
2013
- 2013-02-07 US US13/761,501 patent/US20130216497A1/en not_active Abandoned
2014
- 2014-08-26 JP JP2014171336A patent/JP5985557B2/ja not_active Expired - Fee Related
2016
- 2016-01-14 DO DO2016000017A patent/DOP2016000017A/es unknown
- 2016-02-08 US US15/017,802 patent/US20160222020A1/en not_active Abandoned
- 2016-03-23 AU AU2016201825A patent/AU2016201825B2/en active Active
- 2016-05-27 PH PH12016501009A patent/PH12016501009A1/en unknown
- 2016-08-02 JP JP2016151711A patent/JP6298114B2/ja not_active Expired - Fee Related
- 2016-10-25 IL IL248466A patent/IL248466A/en active IP Right Review Request
2017
- 2017-03-01 US US15/446,102 patent/USRE47221E1/en active Active
- 2017-07-16 IL IL253516A patent/IL253516B/en unknown
- 2017-07-31 CY CY20171100817T patent/CY1119175T1/el unknown
- 2017-07-31 HR HRP20171175TT patent/HRP20171175T1/hr unknown
2018
- 2018-03-07 AU AU2018201663A patent/AU2018201663B2/en active Active
- 2018-09-13 IL IL261778A patent/IL261778A/en unknown
- 2018-12-14 HK HK18116085.2A patent/HK1256947A1/zh unknown
2019
- 2019-06-13 US US16/440,442 patent/US20210061813A1/en not_active Abandoned
2020
- 2020-02-26 AU AU2020201390A patent/AU2020201390A1/en not_active Abandoned
- 2020-03-09 LU LU00149C patent/LUC00149I2/fr unknown
- 2020-03-11 NO NO2020006C patent/NO2020006I1/no unknown
- 2020-03-11 HU HUS2000008C patent/HUS000500I2/hu unknown
- 2020-03-16 CY CY2020007C patent/CY2020007I2/el unknown
- 2020-03-17 LT LTPA2020505C patent/LTC2506716I2/lt unknown
- 2020-03-17 NL NL301035C patent/NL301035I2/nl unknown

Also Published As

Publication number	Publication date
RU2015144809A (ru)	2019-01-11
MX2012006311A (es)	2012-09-12
AU2020201390A1 (en)	2020-03-12
CA2781891A1 (en)	2011-06-09
CL2012001397A1 (es)	2012-09-14
AU2010326108A1 (en)	2012-06-14
CO6561771A2 (es)	2012-11-15
DK2506716T3 (en)	2017-09-04
CR20170159A (es)	2017-06-26
JP2015007094A (ja)	2015-01-15
LT2506716T (lt)	2017-08-25
NL301035I2 (nl)	2020-04-15
JP2013512280A (ja)	2013-04-11
PT2506716T (pt)	2017-08-24
UY33071A (es)	2011-05-31
CN108774237A (zh)	2018-11-09
PE20121336A1 (es)	2012-11-03
HUS2000008I1 (hu)	2020-03-30
CN109053742B (zh)	2021-06-15
HK1256947A1 (zh)	2019-10-04
PH12012501076B1 (en)	2018-07-04
CN109053742A (zh)	2018-12-21
AU2018201663B2 (en)	2020-03-05
IL261778A (en)	2018-10-31
US8426411B2 (en)	2013-04-23
EP2506716B1 (en)	2017-05-17
MX346959B (es)	2017-04-06
CY2020007I2 (el)	2020-11-25
SG181472A1 (en)	2012-07-30
LTPA2020505I1 (lt)	2020-04-10
WO2011068881A1 (en)	2011-06-09
CA2781891C (en)	2018-02-13
RS56317B1 (sr)	2017-12-29
SG10201407976UA (en)	2015-01-29
KR20170118230A (ko)	2017-10-24
BR112012013349B1 (pt)	2019-10-22
CR20120348A (es)	2012-10-04
DOP2016000017A (es)	2016-03-31
US20160222020A1 (en)	2016-08-04
NZ600161A (en)	2014-08-29
TWI600656B (zh)	2017-10-01
KR20180101626A (ko)	2018-09-12
ME02800B (me)	2018-01-20
JP5607174B2 (ja)	2014-10-15
MY167076A (en)	2018-08-10
NO2020006I1 (no)	2020-03-11
LUC00149I2 (nl)	2021-02-15
BR112012013349A2 (pt)	2015-09-15
JP5985557B2 (ja)	2016-09-06
IL253516A0 (en)	2017-09-28
KR101785257B1 (ko)	2017-10-16
IL248466A (en)	2017-07-31
LTC2506716I2 (lt)	2022-06-27
DOP2012000151A (es)	2012-09-30
EP3266786A1 (en)	2018-01-10
IL220054A (en)	2016-10-31
AU2010326108C1 (en)	2018-06-21
LUC00149I1 (nl)	2020-03-09
TW201802091A (zh)	2018-01-16
HUS000500I2 (hu)	2021-03-29
CA2991896A1 (en)	2011-06-09
RU2015144809A3 (nl)	2019-01-11
AU2016201825B2 (en)	2017-12-07
RU2711869C2 (ru)	2020-01-22
KR20140015151A (ko)	2014-02-06
PL2506716T3 (pl)	2017-10-31
CN104370909A (zh)	2015-02-25
EP2506716A4 (en)	2013-05-29
HRP20171175T1 (hr)	2017-10-06
SI2506716T1 (sl)	2017-10-30
USRE47221E1 (en)	2019-02-05
CN102711476B (zh)	2014-12-03
CN104370909B (zh)	2018-09-11
TW201546074A (zh)	2015-12-16
AU2018201663A1 (en)	2018-03-29
AR079234A1 (es)	2012-01-04
IL220054A0 (en)	2012-07-31
ECSP12011979A (es)	2012-07-31
EP3950692A1 (en)	2022-02-09
RU2570416C2 (ru)	2015-12-10
RU2570416C9 (ru)	2019-11-25
AU2016201825A1 (en)	2016-04-14
PH12016501009A1 (en)	2017-10-18
HUE033099T2 (en)	2017-11-28
CN102711476A (zh)	2012-10-03
CY1119175T1 (el)	2018-02-14
JP6298114B2 (ja)	2018-03-20
EP2506716A1 (en)	2012-10-10
TW201125869A (en)	2011-08-01
ES2637588T3 (es)	2017-10-13
CY2020007I1 (el)	2020-05-29
ZA201203999B (en)	2016-01-27
RU2711869C3 (ru)	2022-02-02
US20110311474A1 (en)	2011-12-22
IL253516B (en)	2018-10-31
AU2010326108B2 (en)	2015-12-24
US20210061813A1 (en)	2021-03-04
US20130216497A1 (en)	2013-08-22
PH12012501076A1 (en)	2017-07-21
RU2012127306A (ru)	2014-01-10
TWI500620B (zh)	2015-09-21
JP2017002068A (ja)	2017-01-05

Publication	Publication Date	Title
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I1 (nl)	2020-03-25	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL301305I2 (nl)	2024-12-30	Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301096I2 (nl)	2021-04-12	Filgotinib of een zout daarvan
NL301084I2 (nl)	2021-01-28	remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL301119I2 (nl)	2021-09-15	Selinexor of een farmaceutisch aanvaardbaar zout ervan
NL301028I2 (nl)	2020-04-15	Gilteritinib of een zout ervan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NL301191I2 (nl)	2022-12-07	voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301284I2 (nl)	2024-09-04	Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine
NL301209I2 (nl)	2023-01-24	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300900I2 (nl)	2017-11-16	glecaprevir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL300963I2 (nl)	2021-03-08	inotersen of een zout daarvan
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL301041I2 (nl)	2020-09-14	Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan